Tuis4507 • TYO
add
Shionogi & Co Ltd
Vorige sluiting
ÂĄ3Â 492,00
Dagwisseling
ÂĄ3Â 446,00 - ÂĄ3Â 534,00
Jaarwisseling
ÂĄ2Â 153,50 - ÂĄ3Â 705,00
Markkapitalisasie
3,09Â bn JPY
Gemiddelde volume
2,73Â m
P/V-verhouding
15,15
Dividend-opbrengs
1,90%
PrimĂŞre beurs
TYO
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (JPY) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 147,72Â mjd | 23,48% |
Bedryfskoste | 48,45Â mjd | -3,83% |
Netto inkomste | 74,68Â mjd | 47,39% |
Netto winsgrens | 50,56 | 19,36% |
Wins per aandeel | — | — |
EBITDA | 80,21Â mjd | 36,44% |
Effektiewe belastingkoers | 19,60% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (JPY) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 215,60Â mjd | -29,45% |
Totale bates | 1,73Â bn | 13,94% |
Totale aanspreeklikheid | 213,60Â mjd | 38,72% |
Totale ekwiteit | 1,51 bn | — |
Uitstaande aandele | 850,98 m | — |
Prys om te bespreek | 1,96 | — |
Opbrengs op bates | 11,09% | — |
Opbrengs op kapitaal | 12,36% | — |
Kontantvloei
Netto kontantverandering
| (JPY) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 74,68Â mjd | 47,39% |
Kontant van bedrywe | 32,03Â mjd | -21,48% |
Kontant van beleggings | -26,57Â mjd | -54,23% |
Kontant van finansiering | -29,20Â mjd | -17,14% |
Netto kontantverandering | -18,27Â mjd | -940,68% |
Beskikbare kontantvloei | -10,55Â mjd | -29Â 095,85% |
Meer oor
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Gestig
1878
Hoofkwartier
Webwerf
Werknemers
4Â 955